Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Insights

COVID and the Cardiovascular System
Commentary
COVID and the Cardiovascular System
04/01/2020
Douglas Jennings, PharmD, discusses how COVID-19 interacts with the cardiovascular system, including increasing morbidity in patients with underlying cardiovascular conditions, and provoking myocardial injury.
Douglas Jennings, PharmD, discusses how COVID-19 interacts with the cardiovascular system, including increasing morbidity in patients with underlying cardiovascular conditions, and provoking myocardial injury.
Douglas Jennings, PharmD,...
04/01/2020
Pharmacy Learning Network
Reviewing Treatment Options, Health Outcomes for Patients With Acute Coronary Syndrome
Interview
Reviewing Treatment Options, Health Outcomes for Patients With Acute Coronary Syndrome
04/01/2020
“The message that we learned is that for sure in these patients with AFib and PCI, less is more. Less antithrombotic therapy in other words. Dropping aspirin by the time of hospital discharge and going only with two drugs—a NOAC plus a P2Y12...
“The message that we learned is that for sure in these patients with AFib and PCI, less is more. Less antithrombotic therapy in other words. Dropping aspirin by the time of hospital discharge and going only with two drugs—a NOAC plus a P2Y12...
“The message that we learned is...
04/01/2020
Pharmacy Learning Network
Could There Be a Current Treatment to Prevent Cardiovascular Disease?
Commentary
Could There Be a Current Treatment to Prevent Cardiovascular Disease?
03/16/2020
Mark Munger, PharmD, discusses a category of drugs that can be used as preventative therapy in combination with RAAS inhibitors and statins for reducing cardiovascular disease and events.
Mark Munger, PharmD, discusses a category of drugs that can be used as preventative therapy in combination with RAAS inhibitors and statins for reducing cardiovascular disease and events.
Mark Munger, PharmD, discusses a...
03/16/2020
Pharmacy Learning Network

Advertisement

New Kid on the Block: Bempedoic Acid
Commentary
New Kid on the Block: Bempedoic Acid
03/04/2020
Olajumoke Amuwo, PharmD, MPH, assistant professor of clinical sciences at Roosevelt University College of Pharmacy, discusses the recently approved drug bempedoic acid (Nexletol; Esperion), and highlights important recommendations for...
Olajumoke Amuwo, PharmD, MPH, assistant professor of clinical sciences at Roosevelt University College of Pharmacy, discusses the recently approved drug bempedoic acid (Nexletol; Esperion), and highlights important recommendations for...
Olajumoke Amuwo, PharmD, MPH,...
03/04/2020
Pharmacy Learning Network
Limiting Major CVD Events With Metformin in Vets With Diabetes, Reduced Kidney Function
Interview
Limiting Major CVD Events With Metformin in Vets With Diabetes, Reduced Kidney Function
03/02/2020
Christianne Roumie, MD, MPH, associate professor of Internal Medicine and Pediatrics at Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System, discusses the benefits of the diabetes medication metformin on...
Christianne Roumie, MD, MPH, associate professor of Internal Medicine and Pediatrics at Vanderbilt University Medical Center and the VA Tennessee Valley Healthcare System, discusses the benefits of the diabetes medication metformin on...
Christianne Roumie, MD, MPH,...
03/02/2020
Veterans Health Today
Do We Have the COURAGE to Accept the ISCHEMIA Results?
Commentary
Do We Have the COURAGE to Accept the ISCHEMIA Results?
02/28/2020
Mark Munger, PharmD, discusses the results of two studies and explains why these studies offer pharmacists a greater opportunity to become more involved in stable ischemic heart disease therapy.
Mark Munger, PharmD, discusses the results of two studies and explains why these studies offer pharmacists a greater opportunity to become more involved in stable ischemic heart disease therapy.
Mark Munger, PharmD, discusses...
02/28/2020
Pharmacy Learning Network

Advertisement

Biomarker Prognostic Cocktail in Acute Coronary Syndrome
Commentary
Biomarker Prognostic Cocktail in Acute Coronary Syndrome
02/26/2020
Mark Munger, PharmD, discusses recent studies assessing long-term mortality in relation to acute coronary syndrome (ACS), and he explains why the study results suggest the need for prognostic markers that provide clinicians with risk...
Mark Munger, PharmD, discusses recent studies assessing long-term mortality in relation to acute coronary syndrome (ACS), and he explains why the study results suggest the need for prognostic markers that provide clinicians with risk...
Mark Munger, PharmD, discusses...
02/26/2020
Pharmacy Learning Network
Top Causes of Heart Failure Admissions
Commentary
Top Causes of Heart Failure Admissions
01/22/2020
Mark Munger, PharmD, explains why pharmacists need to be vigilant on medication administration records for all patients, and intervene when necessary to avoid unnecessary drug misadventuring—especially in heart failure.
Mark Munger, PharmD, explains why pharmacists need to be vigilant on medication administration records for all patients, and intervene when necessary to avoid unnecessary drug misadventuring—especially in heart failure.
Mark Munger, PharmD, explains...
01/22/2020
Pharmacy Learning Network
Commentary
Therapeutic Advances in Reducing Thromboembolic Events in HFrEF
12/10/2019
Mark Munger, PharmD, discusses why the search for improving outcomes in HFrEF using newer anti-coagulants continues.
Mark Munger, PharmD, discusses why the search for improving outcomes in HFrEF using newer anti-coagulants continues.
Mark Munger, PharmD, discusses...
12/10/2019
Pharmacy Learning Network

Advertisement

Commentary
Ranolazine-Angiotensin Inhibitor Interactions: Reality or Fantasy?
09/26/2019
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
Mark Munger, PharmD, discusses...
09/26/2019
Pharmacy Learning Network

Advertisement

Advertisement

Advertisement

What's Trending?

News Connection
Low-Value Services Still Costing Insurers Millions
09/15/2016
Nearly 8% of patients out of a national sample of almost 1.5 million commercially insured adults received health services considered low-value in 2013, according to a study in JAMA Internal Medicine. The cost of those services totaled $32.8...
Nearly 8% of patients out of a national sample of almost 1.5 million commercially insured adults received health services considered low-value in 2013, according to a study in JAMA Internal Medicine. The cost of those services totaled $32.8...
Nearly 8% of patients out of a...
09/15/2016
First Report Managed Care
News
Combining newer anticoagulants with some other drugs may be risky
10/03/2017
By...
By...
...
10/03/2017
Population Health
News
HHS Reports 2015 Marketplace will Have 25% More Issuers, Greater Choices and Competition
09/23/2014
According to a report released by the Department of Health and Human Services (HHS), consumers will have more choices as they shop health coverage during the next open enrollment period on the health insurance marketplace for 2015 coverage....
According to a report released by the Department of Health and Human Services (HHS), consumers will have more choices as they shop health coverage during the next open enrollment period on the health insurance marketplace for 2015 coverage....
According to a report released...
09/23/2014
First Report Managed Care
News
Does Lung Disease Affect Mortality in HIV?
03/18/2019
Researchers recently examined the impact obstructive lung disease had on mortality rates among patients with HIV.
Researchers recently examined the impact obstructive lung disease had on mortality rates among patients with HIV.
Researchers recently examined...
03/18/2019
Veterans Health Today
News
Genetically Reduced Vitamin D Levels Tied to Higher MS Risk
09/02/2015
Genetically reduced 25-hydroxyvitamin D levels are associated with an increased risk for MS, according to a new study.
Genetically reduced 25-hydroxyvitamin D levels are associated with an increased risk for MS, according to a new study.
Genetically reduced...
09/02/2015
Pharmacy Learning Network

Advertisement

Stay Informed—Sign up today!

Population Health Newsletter

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use